Adam Raff, M.D., Ph.D.

Adam Raff joined CREATE Medicines as Senior Vice President, Autoimmune Clinical Development in March 2026.

Dr. Raff is a board-certified dermatologist and physician-executive with more than a decade of experience leading clinical development and translational medicine programs in autoimmune and inflammatory diseases. Prior to CREATE, Dr. Raff was Senior Vice President, Clinical Development at Orbital Therapeutics, where his clinical and regulatory strategy supported the company’s $1.5 billion acquisition by Bristol Myers Squibb. At Orbital, he led development of an in vivo CD19 CAR-T therapy for B- cell–mediated autoimmune diseases.

Prior to Orbital, Dr. Raff was Vice President, Head of Clinical Development at Montai Therapeutics, where he advanced multiple programs including the lead asset from discovery into IND-enabling studies. He previously held progressive leadership roles at EQRx (acquired by Revolution Medicines in 2023) as Vice President of Immunology and Senior Medical Director, and at LEO Pharma as Director of Translational Medicine.

Dr. Raff continues to practice dermatology at Beth Israel Lahey Health and holds a faculty appointment at Harvard Medical School. He also serves on the Research Leadership Council of Advancing Innovation in Dermatology.

Dr. Raff received his M.D. and Ph.D. in Systems Biology with an immunology focus from the University of Southern California, completed his dermatology residency at Harvard Medical School, and a research fellowship at Massachusetts General Hospital. He earned his BS in Biology, summa cum laude, from Georgetown University.